<DOC>
	<DOCNO>NCT02143713</DOCNO>
	<brief_summary>A randomize study evaluate continue safety efficacy elagolix management moderate severe endometriosis associate pain adult pre-menopausal female subject complete 6 month treatment Study M12-671 .</brief_summary>
	<brief_title>Global Study Evaluate Long-Term Safety Efficacy Elagolix Subjects With Moderate Severe Endometriosis-associated Pain</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<criteria>Subject complete 6Month Treatment Period pivotal study M12671 . Agrees use require birth control method study Month 6 Posttreatment Followup period Clinically significant gynecological condition Bone mineral density ( BMD ) loss great equal 8 percent spine , femoral neck total hip Plans become pregnant next 18 month</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Dyspareunia</keyword>
	<keyword>Endometriosis-associated pain</keyword>
	<keyword>Dysmenorrhea ( DYS )</keyword>
	<keyword>Elagolix</keyword>
	<keyword>Gonadotropin-releasing Hormone Antagonist</keyword>
	<keyword>Non-menstrual Pelvic Pain ( NMPP )</keyword>
</DOC>